Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma
Related Posts
Tupper HI, Mendelson DS, Doo FX, Carlos RC, Bialecki B, Prosper AE, Moghanaki D, Servais EL, Flores EJ, Cummings AL. Imaging Interoperability: #DitchtheDisk is a[...]
Alkassis S, Suresh Y, Lipsyc-Sharf M, Zhang S, Gianni C, Medford A, Bardia A, Ashouri S, Kapoor N. Circulating tumor DNA detection of local recurrence[...]
Green-Lott AY, Wadhwa A, Bailey AV, Kwan L, Haroldsen CL, Shelton JB, Lewis MS, Beenhouwer DO, Chamie K, Rose BS, Maxwell KN, Nickols NG, Yamoah[...]